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Introduction
Recent data from neoadjuvant studies, predominantly for
endocrine therapy but also for chemotherapy, indicate that a
single measurement of the nuclear proliferation marker Ki67
made in the breast carcinoma during/after neoadjuvant
therapy is strongly predictive of long-term disease outcome.
In an era when many mega-parameter signatures have been
derived with the aim of improving the accuracy of prediction,
it is superficially very surprising that a single immunohisto-
chemical measurement can act in this fashion. This provokes
a number of questions, and the following three are
addressed below: What is the underlying reason for this
predictive ability? Given that Ki67 is influenced by
treatment/external factors and is not stable in the short term,
why does it predict in the long term? What is the best time
for measuring Ki67?
The data
Ki67 is relatively straightforward to measure in formalin-fixed
tissue, being clearly expressed in the nuclei of cells that are
actively proliferating. The MIB1 antibody has been a preferred
diagnostic for many years, but the relatively new antibody
SP6 is now our choice because of its more straightforward
applicability to image analysis [1].
The IMPACT (Immediate Preoperative Arimidex, tamoxifen, or
Combined with Tamoxifen) neoadjuvant trial of anastrozole
versus tamoxifen alone or combined reported that reduction
in Ki67 at 2 weeks and 12 weeks was greater for the
anastrazole alone arm than for either of the other two arms,
mimicking the greater clinical benefit (in terms of increased
recurrence-free survival (RFS)) seen in the equivalent
adjuvant ATAC (Arimidex, Tamoxifen, Alone or in Combina-
tion) trial [2]. Most importantly, follow-up of these patients
indicated that the Ki67 level at 2 weeks was a better
predictor of RFS than pretreatment levels, to the degree that,
in a multivariate model, the 2-week value of Ki67 remained
statistically significant but the pretreatment value was no
longer significant [3].
Similar data at the end of neoadjuvant treatment have been
published for letrozole and tamoxifen in the PO24 trial [4].
These data are important firstly because they add further
validity to changing Ki67 at 2 weeks being an intermediate
marker of effectiveness, thereby supporting the use of this
marker for drug development and studies of mechanisms of
resistance. Secondly, the data indicate that prognostic
evaluation with Ki67 may be better after presurgical therapy.
Lastly, this observation may extend beyond Ki67 such that
multiparameter profiling may be of greater value if conducted
in on-treatment samples.
These data have underpinned the development of the
recently launched POETIC (Peri Operative Endocrine Treat-
ment for Individualising Care CRUK number CRUK/07/015)
trial of the presurgical use or not of a nonsteroidal aromatase
inhibitor in 4,000 oestrogen receptor-positive breast cancer
patients. This study should provide very good power to
evaluate the importance of Ki67 on-treatment to predicting
long-term clinical outcome.
A particularly striking set of data has been derived from our
studies of a single measurement of Ki67 after neoadjuvant
chemotherapy in patients not achieving a pathological
complete remission. Patients in the highest tertile of Ki67 in
the residual tissue at surgery had a median RFS of only about
18 months, while in the lower two tertiles the median RFS
was not reached after 7 years [5].
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What is the underlying reason for the
prediction provided by on-treatment Ki67?
Firstly, it is notable that Ki67 at baseline is a highly prognostic
factor in breast cancer [6]. Many studies confirm that
proliferation is a dominant feature of multigene signatures in
breast cancer. For example, in a study of seven molecular
modules and clinical variables in 628 oestrogen receptor-
positive, HER2-negative breast tumours from public data-
bases, Desmedt and colleagues found that only the prolifera-
tion module (P <10–11) and the grade (P = 0.01) were
significant in multivariate analysis [7].
Secondly, it is clear that the suppression of Ki67 by endo-
crine treatment is profound but variable between patients,
apparently reflecting the variable biological impact of oestro-
gen deprivation. These variable changes result in a pattern of
on-treatment Ki67 in which patients with low Ki67 at baseline
largely maintain this low proliferation but patients with higher
levels may or may not show suppression to that level.
If these changes were associated with the variable impact of
a treatment with modest clinical effects, it is unlikely that the
on-treatment measurements would be of much greater value
than those at baseline. It is clear from studies such as the
Oxford overview analysis [8] and recent adjuvant trials of
aromatase inhibitors versus tamoxifen [9] that the impact of
these treatments in the overall population is very substantial,
however, with the recurrent rate being estimated to be
reduced by an aromatase inhibitor in oestrogen receptor-
positive patients by approximately 50% over the first 5 years.
When is the best time to measure Ki67?
The change in Ki67 values over the first 2 weeks is highly
correlated with changes that occur at 12 weeks after starting
neoadjuvant endocrine therapy. A recent (unpublished)
comparison from the IMPACT trial of RFS at 2 weeks or
12 weeks in patients who have both measurements available
found that, when assessed as a continuous variable, there was
near identical prediction provided by each measurement
(χ2 = 11.5 and χ2 = 11.8 at 2 weeks and 12 weeks,
respectively). It is notable nonetheless that some patients do
show recovery of Ki67 between 2 and 12 weeks. That this
recovery is likely to be meaningful is supported by the latter
population being enriched with HER2-positive patients.
Further work to establish whether this population has a worse
RFS than patients showing persistent Ki67 response at
12 weeks is important to allow the extension of the
neoadjuvant model to the study of early acquired resistance,
both for the purpose of mechanism study and for development
of therapeutics.
Summary and conclusions
If one is interested in assessing prognosis with no account
being taken of the effects of treatment, it would appear that
the most appropriate time to measure Ki67 is at baseline. If,
however, one is interested in also considering the long-term
outcome on a particular endocrine treatment, measurement at
2 weeks or at 12 weeks appears to be of similar value. No
account of pretreatment value is needed in these circum-
stances. If the response of the tumour to a particular
treatment is being evaluated, however, then it is the change
between the baseline and an on-treatment value that is
relevant. A single on-treatment measurement is insufficient for
identifying benefit. Lastly, if one is interested in assessing
only acquired resistance, the change between 2 weeks and a
later time point of at least 12 weeks is needed for the early
recovery of Ki67 levels.
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